Cheng Yong, Yuan Li, Zhao Ming-Wei, Qian Tong
Department of Ophthalmology, People's Hospital, Peking University, Beijing 100044, China.
Eye Diseases and Optometry Institute, College of Optometry, Peking University Health Science Center, Beijing 100044, China.
Int J Ophthalmol. 2021 Mar 18;14(3):416-422. doi: 10.18240/ijo.2021.03.14. eCollection 2021.
To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC).
The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo.
The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, <0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 µm) in comparison with the baseline (510.9±186.1 µm, <0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 µm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted.
IVC is safe and effective for the treatment of DME.
评估玻璃体内注射康柏西普（IVC）治疗糖尿病性黄斑水肿（DME）患者的两年疗效。
回顾性分析30例DME患者（36只眼）的临床资料。患者接受IVC治疗3个月。如有需要，在随后的每月随访中追加IVC（3次加按需给药）。对患者进行24个月的随访。
与基线相比，24个月时最佳矫正视力（BCVA）显著提高（66.7±15.3个字母）（基线为54.4±15.4个字母，P<0.0001）。BCVA的平均改善为11.0±2.9个字母。在24个月时，44.1%的受检眼视力提高≥15个字母，52.9%的眼视力提高≥10个字母，70.6%的眼视力提高≥5个字母。96.8%的眼未出现视力下降，5.9%的眼视力下降≥5个字母，但≤10个字母。与基线相比，24个月时中心视网膜厚度（CRT）显著降低（277.1±122.9μm）（基线为510.9±186.1μm，P<0.0001）。在24个月时，43.3%的患者CRT≤250μm。24个月内的平均注射次数为10.6±2.0次。未观察到与药物或注射相关的严重眼部或全身不良事件。
IVC治疗DME安全有效。
